2-((5-(benzyloxy)pentyl)oxy)acetic acid | 141401-18-5

• 分子结构分类: 有机化合物 - 苯类化合物 - 苯和取代衍生物
• 英文名称: 2-((5-(benzyloxy)pentyl)oxy)acetic acid
• 英文别名: 2-(5-Phenylmethoxypentoxy)acetic acid
• CAS: 141401-18-5
• 化学式: C₁₄H₂₀O₄
• 分子量: 252.31
• InChiKey: CZOVURNMEITNGT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.1
• 重原子数：
  18
• 可旋转键数：
  10
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.5
• 拓扑面积：
  55.8
• 氢给体数：
  1
• 氢受体数：
  4

反应信息

• 作为反应物：
  描述：

  2-((5-(benzyloxy)pentyl)oxy)acetic acid 在 吡啶 、 甲醇 、 硫酸 、 palladium 10% on activated carbon 、 氢气 、 溶剂黄146 、 N,N-二异丙基乙胺 作用下， 以 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 反应 48.5h， 生成 2-((5-(ethyl(2-(4-((2-(3-(3-fluorobenzoyl)-6-hydroxybenzo[b]thiophen-3-yl)oxy)phenoxy)ethyl)amino))pentyl)oxy) acetate
  参考文献：
  名称：

  [EN] TARGETING CHIMERIC COMPOUND, PHARMACEUTICAL COMPOSITION COMPRISING SAME, PREPARATION METHOD THEREFOR AND USE THEREOF
  [FR] COMPOSÉ CHIMÈRE DE CIBLAGE, COMPOSITION PHARMACEUTIQUE LE COMPRENANT, SON PROCÉDÉ DE PRÉPARATION ET SON UTILISATION
  [ZH] 靶向嵌合化合物、含其的药物组合物及其制备方法和用途

  摘要：

  一种靶向嵌合化合物、含其的药物组合物及其制备方法和用途。该靶向嵌合化合物如通式(I)所示，且通式(I)中的各取代基同说明书中的定义相同。与现有技术中的氟维司群相比，该靶向嵌合化合物对雌激素受体α有着相当甚至更优的对突变耐药细胞的增殖抑制活性，从而有望对治疗显示出相当甚至更好的疗效。

  公开号：

  WO2022161166A1
• 作为产物：
  描述：

  5-苄氧基-1-戊醇 、 氯乙酸 在 sodium hydride 作用下， 生成 2-((5-(benzyloxy)pentyl)oxy)acetic acid
  参考文献：
  名称：

  Medium-Membered Ring Ketone Synthesis. Synthesis of Oxa- and Aza-crclooctanone Derivatives.

  摘要：

  作为月桂苷（1）和 FR900482（6）等具有八元环醚或胺框架的天然产物的合成模型研究，我们采用中环酮合成的一般方法，从相应的十二元内酰胺硫化物（49-52）合成了两种 2-苄基氧杂环辛酮（7 和 8）和 2-甲基氮杂环辛酮（9 和 10）。相应的内酰胺硫化物是由含有氧原子（11 和 12）或甲基氨基甲酸酯基团（13 和 14）的线性ω-对甲苯磺酰基羧酸与 2-氰乙基 2-N-甲基氨基苯基硫醚缩合，然后烷基化而容易制备的。

  DOI：

  10.1248/cpb.40.617

文献信息

• TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas, Inc.

  公开号：US20180125821A1

  公开（公告）日：2018-05-10

  The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.

  本公开涉及双功能化合物，其作为tau蛋白的调节剂具有实用性。具体而言，本公开涉及含有一端结合到E3泛素连接酶的VHL或cereblon配体，另一端结合到tau蛋白的双功能化合物，使得tau蛋白与泛素连接酶靠近，以实现tau蛋白的降解（和抑制）。本公开展示了与tau蛋白降解/抑制相关的广泛药理活性。本公开的化合物和组合物用于治疗或预防由tau蛋白聚集或积累导致的疾病或紊乱。
• TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE
  申请人：Arvinas Operations, Inc.

  公开号：EP3999182A1

  公开（公告）日：2022-05-25
• [EN] TAU-PROTEIN TARGETING PROTACS AND ASSOCIATED METHODS OF USE<br/>[FR] PROTACS CIBLANT LA PROTÉINE TAU ET MÉTHODES D'UTILISATION ASSOCIÉES
  申请人：ARVINAS INC

  公开号：WO2018102067A2

  公开（公告）日：2018-06-07

  The present disclosure relates to bifunctional compounds, which find utility as modulators of tau protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tau protein, such that tau protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tau. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tau protein. Diseases or disorders that result from aggregation or accumulation of tau protein are treated or prevented with compounds and compositions of the present disclosure.
• [EN] TAU-PROTEIN TARGETING COMPOUNDS AND ASSOCIATED METHODS OF USE<br/>[FR] COMPOSÉS CIBLANT LA PROTÉINE TAU ET PROCÉDÉS D'UTILISATION ASSOCIÉS
  申请人：ARVINAS OPERATIONS INC

  公开号：WO2021011913A1

  公开（公告）日：2021-01-21

  The present disclosure relates to bifunctional compounds, which find utility as modulators of tan protein. In particular, the present disclosure is directed to bifunctional compounds, which contain on one end a VHL or cereblon ligand which binds to the E3 ubiquitin ligase and on the other end a moiety which binds tan protein, such that tan protein is placed in proximity to the ubiquitin ligase to effect degradation (and inhibition) of tan. The present disclosure exhibits a broad range of pharmacological activities associated with degradation/inhibition of tan protein. Diseases or disorders that result from aggregation or accumulation of tan protein are treated or prevented with compounds and compositions of the present disclosure.
• WO2023/125738
  申请人：——

  公开号：——

  公开（公告）日：——